artelobio.com (ARTL): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Corporate company logo of Artelo Biosciences, Inc. (ARTL)

The success of Artelo Biosciences (ARTL) relies on the legalization of synthetic cannabinoid therapy and the successful completion of clinical trials. A team of molecular biologists is developing innovative drugs, motivated by generous stock options and research freedom. This chart of the market price with an EV/EBITDA ratio of 0.00 confirms the confidence of specialized funds in this ethical brand, which is recognized within the scientific community for the development of lipid platforms.

ARTL Artelo Biosciences, Inc.: Enterprise Value to EBITDA Ratio in the range 11/23/2025 - 11/12/2026

Comprehensive metric breakdowns and analytics for artelobio.com (ARTL)

- current price and projected stock value:
Stock Price Artelo Biosciences, Inc.|ARTL - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value Artelo Biosciences, Inc.|ARTL - Value Adjusted for Debt and Cash
- book value of equity indicators:
Net Assets per Single Share Artelo Biosciences|ARTL - Company Net Assets|Market Capitalization to Book Value Ratio artelobio.com|ARTL - Company Total Assets
- debt and solvency information:
Debt to Equity Artelo Biosciences|ARTL - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Artelo Biosciences, Inc.|ARTL - Company Cumulative Indebtedness|Debts to Book Capitalization Artelo Biosciences, Inc.|ARTL - Long-Term Debt|Company Short-Term Debt Artelo Biosciences|Quick Liquidity artelobio.com
- business earnings and investment ratios data:
ARTL - Company Net Income|Future Profit Artelo Biosciences|ARTL - Company Value to Net Income|Forward P/E Multiple Artelo Biosciences, Inc.|ARTL - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Artelo Biosciences, Inc.|ARTL - Operating income before deduction of amortization|Earnings per share for the last twelve months Artelo Biosciences|ARTL - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months artelobio.com|ARTL - Expected net earnings per share growth this year|Earnings growth forecast for next year Artelo Biosciences
General company analysis:Artelo ARTL
Original product of Artelo Biosciences Inc.

This indicator reflects the ratio of enterprise value, including net debt, to its earnings before interest, taxes, depreciation, and amortization. Analyzing the EV/EBITDA history of the business allows an investor to assess the real value of assets by stripping away the impact of the tax burden and debt structure. For Artelo Biosciences (ARTL), such a metric is critical when evaluating the costs of implementing sustainable farming and transitioning to recycled packaging.

Competitor analysis

EV/EBITDA Multiple INDV (Indivior Group)|EV/EBITDA Multiple Collegium Corp COLL|CRON - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation CGC (canopygrowth.com)|High Tide (HITI) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Aurora Cannabis Inc.|ACHV (Achieve Life Sciences, Inc) - EV/EBITDA Multiple|EV/EBITDA Multiple skyebioscience.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Anebulo Pharmaceuticals (ANEB)|INCR (intercure.co) - Business Value to Operating Income Before Depreciation|Nutriband - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio NSRX (Nasus Pharma Ltd.)|IGC Pharma Inc - EV/EBITDA Multiple|Company Value to EBITDA MIRA Pharmaceuticals|Flora Growth Corp. (FLGC) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IMCC (IM Cannabis) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adial Pharmaceuticals Inc.|Company Value to EBITDA Ensysce ENSC|Enterprise Value to EBITDA Ratio TTNP (Titan Pharmaceuticals)|GNLN (Greenlane Corp) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple INM (InMed Pharmaceuticals)|akandacorp.com - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enveric Biosciences, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Bright Green BGXX|Hempacco (HPCO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization